About Us
The King's Thrombosis Centre is a leading multidisciplinary clinical and research group dedicated to the diagnosis and treatment of hypercoagulable conditions.
We are a designated Haemophilia Centre and were the first National Venous Thromboembolism (VTE) Exemplar Centre, reflecting our national leadership in the prevention and treatment of VTE. Our clinical trials unit works in partnership with industry to develop new treatments for VTE prevention and treatment.
What we do
Patient information
King's Thrombosis Centre are proud to have been the primary exemplar centre within the VTE Network.
Research
We are an experienced multi-disciplinary clinical academic team, conducting translational research in the field of thrombosis and haemostasis.
News
The records below have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at: http://www.evidence.nhs.uk/about-evidence-services/content-and-sources/medicines-information/new-medicines-awareness-services
Study (n=9492 with anticoagulation-associated intracerebral haemorrhage & documented reversal intervention status) found early anticoagulation reversal improved survival (door-to-treatment time ≤60min reduced inpatient mortality [adjusted odds ratio 0.83, 95% CI 0.69-1.00]).
The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at: http://www.evidence.nhs.uk/about-evidence-services/content-and-sources/medicines-information/new-medicines-awareness-services
JAMA Neurology
Science! Have you read the #PEERLESS trial comparing
#thrombectomy (#LBMT) with #catheter-directed #thrombolysis (#CTD) for Intermediate-risk #pulmonary #embolism (#PE)? A critical read and analysis: 🧵1/5
Research
COMING SOON…
MHRA is asking anyone with excessive bleeding due to DOAC to report it to Yellow Card scheme, after which they may be contacted for consent to provide further information & submit a blood sample to explore if they are at higher risk of excessive bleeding due to genetic makeup.
Medicines and Healthcare products Regulatory Agency
Evidence for the interaction between SSRIs and low-dose ASA was found to be weak. It is uncertain whether adding an SSRI to low-dose ASA increases the bleeding risk. Adding low-dose ASA to an SSRI may confer an increased bleeding risk but this is also uncertain.